Reply to Rappaport
et al.
: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
Am J Respir Crit Care Med
.
2020 Dec 15;202(12):1733-1734.
doi: 10.1164/rccm.202007-2913LE.
Authors
Tina Dutt
1
,
David Simcox
1
,
Colin Downey
2
,
Daniella McLenaghan
1
,
Charlotte King
1
,
Manish Gautam
1
,
Steven Lane
3
,
Hassan Burhan
1
Affiliations
1
Liverpool University Hospitals National Health Service Foundation Trust Liverpool, United Kingdom.
2
Liverpool Clinical Laboratories Liverpool, United Kingdom and.
3
University of Liverpool Liverpool, United Kingdom.
PMID:
32931711
PMCID:
PMC7737584
DOI:
10.1164/rccm.202007-2913LE
No abstract available
Publication types
Letter
Comment
MeSH terms
Anticoagulants / therapeutic use
COVID-19*
Drug Monitoring
Humans
SARS-CoV-2
Venous Thromboembolism*
Substances
Anticoagulants